Vertex Pharmaceuticals's Options Frenzy: What You Need to Know
Vertex Pharmaceuticals's Options Frenzy: What You Need to Know
Whales with a lot of money to spend have taken a noticeably bearish stance on Vertex Pharmaceuticals.
有大量资金可以花的鲸鱼对Vertex Pharmicals采取了明显的看跌立场。
Looking at options history for Vertex Pharmaceuticals (NASDAQ:VRTX) we detected 15 trades.
从Vertex Pharmicals（纳斯达克股票代码：VRTX）的期权历史来看，我们发现了15笔交易。
If we consider the specifics of each trade, it is accurate to state that 26% of the investors opened trades with bullish expectations and 46% with bearish.
如果我们考虑每笔交易的具体情况，可以准确地说，26％的投资者以看涨的预期开启交易，46％的投资者持看跌预期。
From the overall spotted trades, 6 are puts, for a total amount of $334,455 and 9, calls, for a total amount of $522,634.
在已发现的全部交易中，有6笔是看跌期权，总额为334,455美元，9笔看涨期权，总额为522,634美元。
What's The Price Target?
目标价格是多少？
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $350.0 and $500.0 for Vertex Pharmaceuticals, spanning the last three months.
在评估了交易量和未平仓合约之后，很明显，主要市场走势者正在关注过去三个月中Vertex Pharmicals在350.0美元至500.0美元之间的价格区间。
Volume & Open Interest Trends
交易量和未平仓合约趋势
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Vertex Pharmaceuticals's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Vertex Pharmaceuticals's substantial trades, within a strike price spectrum from $350.0 to $500.0 over the preceding 30 days.
评估交易量和未平仓合约是期权交易的战略步骤。这些指标揭示了Vertex Pharmicals在指定行使价下期权的流动性和投资者对该期权的兴趣。即将发布的数据可视化了与Vertex Pharmicals大量交易相关的看涨期权和未平仓合约的交易量和未平仓合约的波动，在过去30天内，行使价范围从350.0美元到500.0美元不等。
Vertex Pharmaceuticals 30-Day Option Volume & Interest Snapshot
Vertex Pharmicals 30 天期权交易量和利息
Significant Options Trades Detected:
检测到的重要期权交易：
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| VRTX | CALL | SWEEP | BULLISH | 06/21/24 | $80.9 | $75.0 | $79.0 | $360.00 | $134.3K | 212 | 20 |
| VRTX | CALL | TRADE | BEARISH | 06/14/24 | $68.5 | $61.9 | $64.5 | $375.00 | $129.0K | 0 | 20 |
| VRTX | PUT | SWEEP | BEARISH | 06/21/24 | $6.3 | $5.9 | $6.2 | $430.00 | $114.5K | 103 | 199 |
| VRTX | PUT | SWEEP | BEARISH | 06/21/24 | $6.5 | $6.4 | $6.4 | $430.00 | $96.6K | 103 | 385 |
| VRTX | CALL | SWEEP | BULLISH | 06/21/24 | $10.0 | $9.7 | $10.0 | $440.00 | $48.0K | 434 | 77 |
| 符号 | 看跌/看涨 | 交易类型 | 情绪 | Exp。日期 | 问 | 出价 | 价格 | 行使价 | 总交易价格 | 未平仓合约 | 音量 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| VRTX | 打电话 | 扫 | 看涨 | 06/21/24 | 80.9 美元 | 75.0 美元 | 79.0 美元 | 360.00 美元 | 134.3 万美元 | 212 | 20 |
| VRTX | 打电话 | 贸易 | 粗鲁的 | 06/14/24 | 68.5 美元 | 61.9 美元 | 64.5 美元 | 375.00 美元 | 129.0K | 0 | 20 |
| VRTX | 放 | 扫 | 粗鲁的 | 06/21/24 | 6.3 美元 | 5.9 美元 | 6.2 美元 | 430.00 美元 | 114.5 万美元 | 103 | 199 |
| VRTX | 放 | 扫 | 粗鲁的 | 06/21/24 | 6.5 美元 | 6.4 美元 | 6.4 美元 | 430.00 美元 | 96.6 万美元 | 103 | 385 |
| VRTX | 打电话 | 扫 | 看涨 | 06/21/24 | 10.0 美元 | 9.7 美元 | 10.0 美元 | 440.00 美元 | 48.0 万美元 | 434 | 77 |
About Vertex Pharmaceuticals
关于 Vertex 制药
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Vertex Pharmaceuticals是一家全球生物技术公司，致力于发现和开发用于治疗严重疾病的小分子药物。其主要药物是治疗囊性纤维化的Kalydeco、Orkambi、Symdeko和Trikafta/Kaftrio，其中Vertex疗法仍然是全球的护理标准。Vertex通过Casgevy实现了其产品组合的多元化，Casgevy是一种治疗β地中海贫血和镰状细胞病的基因编辑疗法。此外，Vertex正在评估使用非阿片类药物治疗的针对急性和慢性疼痛的小分子抑制剂，以及针对APOL1介导的肾脏疾病的小分子抑制剂。Vertex还在研究细胞疗法，为1型糖尿病提供潜在的功能性治疗方法。
In light of the recent options history for Vertex Pharmaceuticals, it's now appropriate to focus on the company itself. We aim to explore its current performance.
鉴于Vertex Pharmicals最近的期权历史，现在应该将重点放在公司本身上。我们的目标是探索其目前的表现。
Present Market Standing of Vertex Pharmaceuticals
Vertex 制药目前的市场地位
- With a volume of 1,057,724, the price of VRTX is up 2.08% at $437.49.
- RSI indicators hint that the underlying stock may be overbought.
- Next earnings are expected to be released in 76 days.
- VRTX的交易量为1,057,724美元，上涨2.08％，至437.49美元。
- RSI 指标暗示标的股票可能处于超买状态。
- 下一份财报预计将在76天后公布。
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Vertex Pharmaceuticals options trades with real-time alerts from Benzinga Pro.
期权交易具有更高的风险和潜在的回报。精明的交易者通过不断自我教育、调整策略、监控多个指标以及密切关注市场走势来管理这些风险。借助Benzinga Pro的实时警报，随时了解最新的Vertex Pharmicals期权交易。